JOHN BLAKEMORE: Open Payments
NPI 1548837610 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,180 in 36 payments from 12 companies in 2025. Trend: 2023 $5,015 · 2024 $5,144 · 2025 $1,180
Food & beverage: $1,180
| Company | Payments | Amount |
|---|---|---|
| SK Life Science, Inc. | 8 | $331 |
| Biogen, Inc. | 7 | $167 |
| Grifols USA, LLC | 1 | $150 |
| JAZZ PHARMACEUTICALS INC. | 3 | $89 |
| ABBVIE INC. | 4 | $70 |
| UCB, Inc. | 3 | $61 |
| Ceribell, Inc. | 1 | $60 |
| Alexion Pharmaceuticals, Inc. | 2 | $59 |
| GENZYME CORPORATION | 2 | $56 |
| Janssen Biotech, Inc. | 2 | $52 |
Products named: TYSABRI, Gamunex-C, XCOPRI, EPIDIOLEX, POCKET EEG DEVICE, ULTOMIRIS, Ocrevus Zunovo, Nayzilam.
Industry payments across NV — which companies pay providers there.
